or Try an Advanced Search...

    ETF Components for CANC - Tema Oncology ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    REGN D -0.63 6.07
    MRK F -2.32 4.26
    ARGX A 0.50 4.19
    AMGN D -0.18 3.78
    BPMC F 0.84 3.30
    ILMN B 7.78 3.27
    RVMD B 1.79 3.13

    Represented by ETF Holdings

    Keywords: Medicine Biopharmaceutical Biotechnology Cancer Inflammation Nasdaq 100 S&P 500 Bone Clinical Research Dow Jones Component Infectious Diseases Life Sciences Obesity Ophthalmology Pharmaceutical Products Rheumatoid Arthritis Acid Acute Myeloid Leukemia Amines Angiogenesis
    Industries: Biotechnology Drug Manufacturers - Major Diagnostics & Research

    Recent News for Tema Oncology ETF & its Holdings

    Date Stock Title
    Oct 2 ARGX Biotech Leader Argenx In Buy Zone, Poised To Hit New Highs
    Oct 2 ILMN Illumina, Inc. (ILMN): A Bull Case Theory
    Oct 2 AMGN Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now
    Oct 1 MRK U.S. port strike expected to have limited impact on healthcare supply chain: HHS
    Oct 1 AMGN Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi
    Oct 1 AMGN LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
    Oct 1 MRK Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
    Oct 1 MRK Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
    Sep 30 AMGN Amgen must face lawsuit claiming it hid $10.7 billion tax bill
    Sep 30 REGN Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
    Sep 30 ILMN Shareholders in Illumina (NASDAQ:ILMN) are in the red if they invested three years ago
    Sep 30 MRK Merck & Co. Inc. (MRK): A Strong Investment as KEYTRUDA Sales Drive Revenue Growth
    Sep 30 AMGN Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
    Sep 30 MRK Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth
    Sep 30 AMGN Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
    Sep 29 REGN Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
    Sep 29 REGN Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
    Sep 29 AMGN Institutional investors may overlook Amgen Inc.'s (NASDAQ:AMGN) recent US$7.9b market cap drop as long-term gains remain positive
    Sep 29 MRK Is Merck Stock a Buy?
    Sep 29 REGN Regeneron: Long-Term Defensive Investment
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
    Index Fund Investment Management Private Equity
    Back to the Main CANC Page...